Non-Covered Product: payments to doctors
Payments that named Non-Covered Product as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $7.1M
- Providers
- 1,457
- Transactions
- 4,809
- Average per transaction
- $1,476
The per-transaction average — $1,476 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 1,457 providers the average total is $4,872, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Genentech, Inc. | $3,081,468 | 43.4% |
| F. Hoffmann-la Roche AG | $2,504,063 | 35.3% |
| Genentech USA, Inc. | $912,790 | 12.9% |
| Chugai Pharmaceutical Co., Ltd. | $323,736 | 4.6% |
| Roche Products Limited | $150,309 | 2.1% |
| Hoffmann-la Roche Limited | $71,182 | 1.0% |
| Roche TCRC, Inc. | $55,035 | 0.8% |